Organon & Co. (OGN) · Oct 30, 2026 · Earnings
Beat — Adjusted EPS $0.94 vs ~$0.88 consensus
Organon’s Q3 earnings beat adjusted EPS estimates, though adjusted EBITDA declined and margins weakened, keeping the turnaround under pressure.
Organon is trying to hold a roughly flat 2026 business while deleveraging and reinvesting around women’s health, biosimilars and established medicines; its prior full-year plan called for about $6.2 billion of revenue and $1.9 billion of adjusted EBITDA, broadly matching 2025. The quarter cleared the earnings bar, but only narrowly. Adjusted diluted EPS was $0.94 versus a published consensus of roughly $0.88, a modest beat; GAAP diluted EPS was essentially flat year over year at $0.60 versus $0.61. The filing is supplemental rather than a full earnings release: 〔0〕
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Adjusted diluted EPS (GAAP Diluted Earnings per Share) | $0.94 | $1.01 | ~$0.88 |
| GAAP diluted EPS (GAAP Diluted Earnings per Share) | $0.60 | $0.61 | |
| Adjusted EBITDA (Adjusted EBITDA table) | $502M | $518M | |
| Adjusted EBITDA margin (Adjusted EBITDA table) | 31.9% | 32.3% |
The underlying operating trend remains soft. Adjusted EBITDA fell 3.1% year over year to $502 million, while margin contracted 40 basis points to 31.9%; the nine-month figures are weaker still, with adjusted EBITDA down to $1.378 billion from $1.524 billion and margin down to 30.0% from 32.4%. That means the EPS beat came alongside continued pressure on the profit engine, not a clear acceleration in the business.
Cost actions are helping, but they are not yet reversing the earnings trend. Nine-month adjusted SG&A declined to $1.188 billion from $1.198 billion and adjusted R&D fell to $243 million from $252 million, while manufacturing-network costs were lower. But adjusted net income still dropped to $674 million from $789 million, and adjusted EPS fell to $2.51 from $3.03 for the first nine months. The filing also shows the company is still absorbing transition costs tied to exiting manufacturing and supply agreements with Merck and to the Dermavant transaction.
Bottom line: This is a narrow earnings beat, not a clean operational reacceleration. It modestly improves the quarter versus expectations, but the broader Organon story remains one of declining adjusted profitability and compressed margins while management works through its portfolio and cost transition.
Q4 results and 2027 outlook
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!